Interim Management Statement

FINSBURY WORLDWIDE PHARMACEUTICAL TRUST PLC                  

      Interim Management Statement - 3 months to 30 June 2007 (unaudited)      

Finsbury Worldwide Pharmaceutical Trust PLC invests in pharmaceutical and
biotechnology companies worldwide with the aim of achieving a high level of
capital growth.

The 3 month period ending 30 June 2007 was a volatile one for the
pharmaceutical sector which saw the Company's undiluted net asset value per
share rise by 2.8% compared to a rise of just 0.3% in the Company's benchmark,
the Datastream World Pharmaceutical and Biotechnology Index measured in
sterling terms on a total return basis. June proved to be the difficult month
in the period, where some gains made earlier in the period were given back, the
Company's undiluted net asset value per share falling by 4.5%, in line with the
decline in the benchmark.

The Company's share price rose by 1.7% during the three-month period as the
discount of share price to the undiluted net asset value per share widened
slightly from 8.1% to 9.1%. During the period a total of 1,878,000 shares were
repurchased for cancellation at a cost of £9.3m (including expenses).
Subsequent to the period-end, 14,687 new fully paid Ordinary shares were
allotted and issued following the receipt of notices to exercise warrants at an
exercise price of 464p on the exercise date of 31 July 2007.

Trust Characteristics

                           30 June 2007               31 Mar 2007              
                                                                               
Number of holdings         40                         33                       
                                                                               
Net assets (£m)            270.7                      273.0                    
                                                                               
Net yield                  0.6%                       0.4%                     
                                                                               
Gearing (AIC basis)        114                        105                      
                                                                               
Share price (p)            486.00                     477.75                   
                                                                               
NAV (p) -undiluted         534.53                     519.78                   
                                                                               
NAV (p) diluted: warrants  522.16                     510.29                   
                                                                               
NAV (p) - fully diluted    519.34                     507.87                   
for                                                                            
                                                                               
warrants and treasury                                                          
shares                                                                         
                                                                               
(Discount)/premium         (9.1%)                     (8.1%)                   
(undiluted)                                                                    
                                                                               
(Discount/premium(diluted  (6.9%)                     (6.4%)                   
- warrants)                                                                    
                                                                               
(Discount/premium (fully   (6.4%)                     (5.9%)                   
diluted)                                                                       
                                                                               
Warrant price (p)          98.50                      103.00                   

Source: Frostrow Capital LLP

10 Largest Investments

Name                                 % of                      % of           
                             investment portfolio      investment portfolio   
                                at 30 June 2007           at 31 Mar 2007      
                                                                              
Novartis                              6.8                       7.4                      
                                                                              
Wyeth                                 5.1                       6.4                      
                                                                              
Gen-Probe                             4.9                       4.2                      
                                                                              
Genentech Inc                         4.6                       7.2                      
                                                                              
Amgen                                 4.5                       5.0                      
                                                                              
Johnson & Johnson                     4.4                       5.3                      
                                                                              
Pfizer                                4.3                       7.2                      
                                                                              
Takeda Pharmaceutical                 4.2                       4.6                      
                                                                              
Genzyme                               3.8                       3.8                      
                                                                              
Biogen                                3.8                       3.4                      
                                                                              
Total                                46.4                                               

Source: Frostrow Capital LLP

Sector Analysis

                                      % of                       % of           
                                                                                
                              investment portfolio       investment portfolio   
                                                                                
                                at 30 June 2007             at 31 Mar 2007      
                                                                                
Large capitalisation                  65.9                       71.5           
                                                                                
Small capitalisation                  34.1                       28.5           
                                                                                
Total                                100.0                      100.0           

Source: Frostrow Capital LLP

Geographical Analysis

                                     % of                       % of           
                                                                               
                             investment portfolio       investment portfolio   
                                                                               
                               at 30 June 2007             at 31 Mar 2007      
                                                                               
North America                        71.9                       75.4           
                                                                               
Europe                               14.6                       11.9           
                                                                               
Japan                                13.5                       12.7           
                                                                               
Total                               100.0                      100.0           

Source: Frostrow Capital LLP

Total Return Performance

                3 Months        1 Year          3 Years         5 Years        
                                                                               
Share price     +2.3%           +1.0%           +4.4%           +13.4%         
                                                                               
NAV Fully       +2.8%           +5.8%           +7.8%           +27.0%         
diluted                                                                        
                                                                               
Benchmark*      +0.3%           +2.0%           +18.3%          +15.3%         

Source: NAV (total return; fully diluted) and Share Price (total return)
Fundamental Data. Benchmark - Thomson Financial Ltd.

* Benchmark - Datastream World Pharmaceutical and Biotechnology Index measured
in sterling terms on a total return basis.

Past performance is not a guide to future performance.

This interim management statement is available on the Company's website 
www.finsburywp.com.

The Company's Net Asset Value per share is announced daily and is available,
together with the share price, on the TrustNet website at www.trustnet.com

For further information contact: Mark Pope on 0203 008 4913

Frostrow Capital LLP

Company Secretary

10 August 2007